Firstly, AML patients had highly heterogeneous clinical characteristics in terms of pre‐transplant TKIs usage, conditioning intensity, pre‐ and post‐transplant MRD status, FLT3i administration schedule, and NPM1 co‐mutations. Here, NPM1 is linked to acute myeloid leukemia.